Abstract: The disclosure provides technology for enhancing the ability of a computing device to detect when a user has discontinued reading a text source. An example method includes receiving audio data comprising a spoken word associated with a text source, comparing the audio data with data of the text source, determining, based on the comparing, whether a segment of the audio data corresponds to a location of the text source, and responsive to determining that the segment of the audio data does not correspond to a location of the text source, transmitting a signal indicating that a user has discontinued reading the text source, the signal causing to cease the comparing of the audio data with the data of the text source.

Abstract: A display may have a pixel array such as a liquid crystal pixel array. The pixel array may be illuminated with backlight illumination from a direct-lit backlight unit. The backlight unit may include an array of light-emitting diodes (LEDs) on a printed circuit board. The display may have a notch to accommodate an input-output component. Reflective layers may be included in the notch. The backlight may include a color conversion layer with a property that varies as a function of position. The light-emitting diodes may be covered by a slab of encapsulant with recesses in an upper surface.

Abstract: Compositions and methods are provided for the reversible modification of RNA to enhance RNA in-solution and enzymatic stability by reaction with acylimidazoles, sulfonyltriazoles, or sulfonylimidazoles. 2?-OH acylation protects RNA from hydrolytic and enzymatic degradation. Water-soluble organocatalysts can accelerate the reversal of acylation adducts and functionally restore RNAs, alternatively the acylation is spontaneously reversed in a cellular environment. Chemically tuned 2?-OH acylation can be spontaneously released in cells to restore RNA biological functions including translation. mRNA can be selectively modified at the 2?-OH of poly(A)-tail for enhanced in-cell stability and enhanced total protein output.

Abstract: A method for setting an axial position and gap dimension of a gap between one or more score blades and an anvil shaft of a rotary scoring device, includes providing a control system including a controller, at least one sensor, and at least one adjusting device actuated by the control system, and actuating the at least one adjusting device in response to the at least one sensor sensing a deviation from a desired state, thereby setting the axial position or the gap dimension between the one or more score blades and the anvil shaft. The method further includes actuating the at least one adjusting device is achieved as a result of the control system operating in a closed feedback loop, and sensing by the at least one sensor occurring with or without disruption of operation of the rotary scoring device.

Abstract: In one aspect, a computerized method for determining a probability value that a real-estate asset is to be placed on the market for sale includes the step of obtaining a database of real-estate assets. The method includes the step of merging a set of similar near real-estate tracts using a breadth-first search. The method, includes the step of creating a submarket of real-estate assets by performing duster analysis with a hierarchal-clustering method in a county context. The method includes the step of identifying a set of datasets of real-estate assets on a per-county level. The method includes the step of identifying a set of datasets of real-estate assets on a per-state level. The method includes the step of determining a probability that each real-estate asset will be placed for sale based on a set of geo-models. The method includes the step of mapping the probability that each real-estate asset will be placed for sale to a score.

Abstract: Disclosed herein are methods for preparing [1,2,4]triazolo[4,3-a]pyridines, particularly (R)-6-(1-(8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, and precursors thereof, such as a method comprising reacting (R)—N-(3-fluoro-5-(1methyl-1H-pyrazol-4-yl) pyridin-2-yl)-2-(3-(2-methoxyethoxy)-5-oxo-1,6-naphthyridin-6(5H)yl) propanehydrazide (“HYDZ”): (HYDZ) under conditions sufficient to form (R)-6-(1-(8-fluoro-6-(1-methyl-IH-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (“A”): (A)

Abstract: Disclosed herein are methods for preparing [1,2,4]triazolo[4,3-a]pyridines, particularly (R)-6-(1-(8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, and precursors thereof, such as a method comprising reacting (R)—N-(3-fluoro-5-(1methyl-1H-pyrazol-4-yl) pyridin-2-yl)-2-(3-(2-methoxyethoxy)-5-oxo-1,6-naphthyridin-6(5H)yl) propanehydrazide (“HYDZ”): (HYDZ) under conditions sufficient to form (R)-6-(1-(8-fluoro-6-(1-methyl-IH-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (“A”): (A)

Abstract: In one aspect, a method of generating a prediction list of real-estate assets that have a specified probability of being placed for sale within a specified period of time includes the step of providing a list of real-estate assets. Each real-estate asset is associated with one or more real-estate assets attributes. The method includes the step of providing a training data set wherein the training data set comprises a past population of data associated with a plurality of real-estate assets and a set of training-data set attributes for each real-estate asset in the plurality of real-estate assets. The method includes providing a testing data set wherein the testing data set comprises another past population of data associated with the plurality of real-estate assets and a set testing-data set attributes for each real-estate asset in the plurality of real-estate assets, wherein the set of testing data set attributes comprises an updated version of the training data set attributes from a specified later time.

Abstract: Various disclosed embodiments include methods and systems for configuration and management of an electronic control unit (ECU). According to disclosed embodiments, a method for configuration and management of an ECU includes receiving by a data processing system at least one calibration parameter and a corresponding value for the ECU and generating by the data processing system virtual memory locations representing physical memory locations of the ECU. The method includes receiving by the data processing system allocations for the virtual memory locations, wherein the allocations identify blocks and sub-blocks allocated to the calibration parameter and the corresponding value. The method includes generating and storing by the data processing system an output responsive to the allocations, wherein the output contains a memory layout of the stored parameter and the value, and wherein the output is configured to be stored in the physical memory locations of the ECU.

Abstract: An electron donor composition comprising a dihydroanthracene derivative and a phthalate ester. Furthermore, a solid catalyst composition comprising the electron donor composition for use in ?-olefin polymerisation. Further, a process for the production of a polymer containing ?-olefin monomer units with the electron donor composition.

Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.

Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.

Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.